



# Proteomics International

LABORATORIES LTD

ASX/Media Release

30 March 2017

ASX code: PIQ

## Release from mandatory escrow and proposed voluntary escrow

In April 2017, medtech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) will reach its second anniversary since admission to the Official List of the ASX. At that time, over 49% of shares on issue will be released from ASX mandatory escrow.

Proteomics advises pursuant to ASX Listing Rule 3.10A that 29,251,563 unquoted fully paid ordinary shares, 3,110,000 options exercisable at \$0.20 per option and expiring 31 March 2018 together with 175 performance rights are due to be released from mandatory escrow on 16 April 2017.

**The Directors, who together hold 39% of shares on issue, have each committed to entering into voluntary escrow arrangements with the Company for a further 12-month period in respect of the 22,967,970 shares held, subject to the granting of ASIC relief.**

PILL's Chairman Terry Sweet said "The Directors are proud to signify their committed support to the Company, confidence in the Proteomics business model and opportunities for growth in both cash-flow and deal-flow in 2017 and onwards".

Proteomics International will apply to ASX for quotation of these securities under separate cover.

ENDS

### For further information please contact:

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Susan Fitzpatrick-Napier [Media Contact]  
Digital Mantra Group  
T: +61 2 8218 2144  
E: [team@dmgpr.com](mailto:team@dmgpr.com)

Greg Wood [Corporate Advisor]  
Managing Director  
K S Capital  
T: +61 416 076 377  
E: [g.wood@kscapital.com.au](mailto:g.wood@kscapital.com.au)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA, 6009 Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

## **About Proteomics International Laboratories (PILL)**

PILL (ASX: PIQ) is a medical technology company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas, each massive growth markets:

- 1. Diagnostics:** Biomarkers of disease and personalised medicine - focus on diabetic kidney disease.  
By 2020 the biomarkers market is estimated to double in size to \$45.6 billion, and the personalised medicine market is forecast to be worth over \$149 billion.
- 2. Analytical services:** Specialist contract research fee-for-service model – focus on biosimilars QC.  
The global biosimilars market is expected to reach \$6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.
- 3. Drug discovery:** Therapeutic peptide drug discovery - focus on painkillers and antibiotics.  
The global peptide therapeutics market is currently estimated to be worth \$18 billion and is expected to increase at over 10% per year during 2016-2025.

In combination these areas offer, respectively, medium term products, near term cash flow, and blue sky potential by harnessing one complementary workflow centred on proteins.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA, 6009 Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)